Cystotech Is an AI MedTech company working in the field of Urology to transform the future of bladder cancer treatment. We are developing applications for use during cystoscopy of the bladder and are focused on better diagnostics performance and the use of less invasive approaches to treatment for the benefit of patients and healthcare costs.
Bladder cancer has a high recurrence and progression rate. In order to reduce the recurrence rate, knowledge of the tumor grade is essential to perform resection to the correct depth of the layers in the urinary bladder during primary resection of the tumor. However, visual estimation by the surgeon regarding tumor grade is very poorly correlated to the true tumor grade. This is the main reason for the high recurrence rate and delay of relevant adjuvant treatment.
Cystotech develops deep-tech health solutions to foster health digitalization with high diagnostic performance.
Bladder cancer Patients are prone to develop multiple recurrences. Our aim is to reduce surgical procedures for the benefit of their quality of life.
Cystotech is dedicated to developing solutions that can transform the current clinical pathway.
We believe that deep-tech health solutions will change the future of healthcare toward improved personalized treatment.
At Cystotech, our Quality Management System is designed to align with customer requirements and applicable regulatory standards. As a developer and distributor of software as medical devices (SaMD), we prioritize safety and customer satisfaction while ensuring compliance with all regulations. Our commitment extends to providing AI-based support for bladder cancer treatment decisions, fulfilling customer requirements, and enhancing patient outcomes. We achieve this through a risk-based approach, competent employees, and ambitious Quality Objectives that focus on regulatory compliance, customer expectations, process efficiency, operational excellence, and continuous improvement. Through regular monitoring and Management Reviews, we ensure the ongoing suitability of our employees, products, and processes.